




RealRate

PHARMACEUTICAL 2021

Ayala Pharmaceuticals Inc
Rank 179 of 394

ADVAXIS
IMMUNOTHERAPIES™



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Ayala Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 24% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	27,851
Cost of Goods Sold	0
Intangible Assets	3,261
Liabilities, Current	3,291
Liabilities, Non-Current	5,055
Other Assets	5,021
Other Compr. Net Income	0
Other Expenses	130
Other Liabilities	0
Other Net Income	110
Other Revenues	253
Property and Equipment	2,393
Research and Development	15,612
Selling, General and Administrative Expense	11,090

Output Variable	Value in 1000 USD
Assets	38,526
Liabilities	8,346
Expenses	26,832
Revenues	253
Stockholders Equity	30,180
Net Income	-26,469
Comprehensive Net Income	-26,469
BaseVar	37,034
ECR before Limited Liability	168%
Economic Capital Ratio	280%